A ganglioside in which the oligosaccharide portion is composed of a trisaccharide, to which one or more sialic acid residues are attached.
ChEBI ID: 36541
Member | Definition | Role |
---|---|---|
g(m2) ganglioside | A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is octadecanoyl. A constituent of natural ganglioside GM2. | ganglioside GM2 (18:0) |
g(m3) ganglioside | A sialotriaosylceramide consisting of beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide(d18:1/24:1(15Z)). | 3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)).html>alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)); ganglioside GM3 |
n-glycolylneuraminyllactosylceramide | A sialotriaosylceramide in which the triaosyl group is 3,5-dideoxy-5-(2-hydroxyacetamido)-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl attached to the primary hydroxy function of ceramide. A tumour antigen found in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but not usually detected in normal human cells. | N-glycolylneuraminyllactosylceramide |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 392 (24.32) | 18.7374 |
1990's | 468 (29.03) | 18.2507 |
2000's | 403 (25.00) | 29.6817 |
2010's | 275 (17.06) | 24.3611 |
2020's | 74 (4.59) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 35 (1.95%) | 5.53% |
Reviews | 118 (6.57%) | 6.00% |
Case Studies | 89 (4.96%) | 4.05% |
Observational | 1 (0.06%) | 0.25% |
Other | 1,552 (86.46%) | 84.16% |